| Dec'19 | Dec'18 | |||||
|---|---|---|---|---|---|---|
CASH FLOWS FROM OPERATING ACTIVITIES | ||||||
Net loss | ||||||
-43,755 | -81,714 | |||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Stock-based compensation expense | ||||||
1,770 | 121 | |||||
Shares issued in connection with Amgen Agreement | ||||||
- | -1,353 | |||||
Acquisition of technology in connection with Amgen Agreement | ||||||
- | 5,000 | |||||
Issuance date fair-value of anti-dilution liability | ||||||
- | 1,639 | |||||
Change in fair value of preferred stock tranche liability | ||||||
- | 62,150 | |||||
Change in fair value of anti-dilution right liability | ||||||
- | 5,765 | |||||
Net amortization of premiums and discounts on short-term investments | ||||||
104 | - | |||||
Changes in operating assets and liabilities: | ||||||
Prepaid expenses and other assets | ||||||
507 | 1,059 | |||||
Accounts payable | ||||||
-426 | 1,313 | |||||
Accrued expenses and other current liabilities | ||||||
7,395 | 807 | |||||
Net cash used in operating activities | ||||||
-35,627 | -4,625 | |||||
CASH FLOWS FROM INVESTING ACTIVITIES | ||||||
Purchase of short-term marketable securities | ||||||
71,513 | - | |||||
Acquisition of technology in connection with Amgen Agreement | ||||||
- | 5,000 | |||||
Net cash used in investing activities | ||||||
-71,513 | -5,000 | |||||
CASH FLOWS FROM FINANCING ACTIVITIES | ||||||
Proceeds from issuance of common stock in initial public offering, net of issuance costs and underwriting fees | ||||||
95,452 | - | |||||
Proceeds from the early exercise of stock options in exchange for restricted common stock | ||||||
321 | - | |||||
Proceeds from the exercise of stock options | ||||||
130 | 8 | |||||
Proceeds from the issuance of common stock pursuant to employee stock purchase plan purchases | ||||||
85 | - | |||||
Payment of initial public offering costs | ||||||
- | 52 | |||||
Payment of preferred stock issuance costs | ||||||
- | 449 | |||||
Net cash provided by (used in) financing activities | ||||||
95,988 | 85,007 | |||||
Net decrease in cash, cash equivalents and restricted cash | ||||||
-11,152 | 75,382 | |||||
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION: | ||||||
Conversion of convertible preferred stock into common stock | ||||||
124,728 | - | |||||
Net unrealizable gain on marketable securities | ||||||
-6 | - | |||||
Accretion of redeemable convertible preferred stock to redemption value | ||||||
- | 520 | |||||
Issuance date fair value of preferred stock tranche obligation | ||||||
- | 7,350 | |||||
Deferred offering costs included in accounts payable and accrued expenses and other current liabilities | ||||||
- | 309 | |||||
Shares issued in connection with Amgen Agreement | ||||||
- | -1,353 | |||||
Settlement of future purchase obligation | ||||||
- | -32,750 | |||||
Extinguishment of call option liability | ||||||
- | 36,750 | |||||
Series A Preferred Stock | ||||||
Proceeds from issuance of redeemable convertible preferred stock | ||||||
- | 40,000 | |||||
Issuance of Series A redeemable convertible preferred stock in settlement of anti dilution right liability | ||||||
- | 7,404 | |||||
Series B Preferred Stock | ||||||
Proceeds from issuance of redeemable convertible preferred stock | ||||||
- | 45,500 | |||||